Advertisement
Novartis
Subscribe to Novartis

The Lead

Photo of the Day: Meningitis Vaccine

February 25, 2015 2:19 pm | by Mike Auerbach, Editor-In-Chief | News | Comments

Until recently, there was no vaccine available in the US to help protect against meningococcal group B, one of the most prevalent types of meningococcal meningitis in the US.

FDA Approves Farydak for Treatment of Multiple Myeloma

February 24, 2015 10:14 am | News | Comments

The U.S. Food and Drug Administration has approved Farydak (panobinostat) for the treatment of...

Photo of the Day: Novartis CEO Joe Jimenez

January 28, 2015 11:16 am | by Mike Auerbach, Editor In Chief | News | Comments

It’s financial reporting season and the pharmaceutical industry is no exception. This week...

Novartis Posts Fourth Quarter Profit Drop

January 27, 2015 6:53 am | News | Comments

Novartis AG says fourth quarter net income dropped 26 percent but the company still posted a...

View Sample

FREE Email Newsletter

Array BioPharm to Acquire Novartis’ Encorafenib

January 23, 2015 8:23 am | News | Comments

Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.        

FDA Approves Novartis’ Cosentyx for Moderate-to-Severe Plaque Psoriasis

January 21, 2015 2:12 pm | News | Comments

Novartis announced that the FDA has approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.         

FDA Panel Endorses Novartis' Biosimilar

January 8, 2015 8:34 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

A panel of Food and Drug Administration experts ruled that the Novartis' version of Neupogen is highly similar to Amgen's original blockbuster biotech drug, which is used to boost blood cells that help cancer patients fight off infections.  

Advertisement

Lilly Closes Novartis Deal to Create Huge Animal Health Business

January 2, 2015 8:17 am | News | Comments

Just over a week after saying it would sell its heartworm treatment for dogs at the request of federal regulators, Eli Lilly announced that it has completed its $5.4 billion acquisition of the animal health division belonging to Switzerland's Norvartis.

FDA Approves Novartis’ Signifor for Acromegaly

December 16, 2014 8:12 am | News | Comments

Acromegaly is a rare, debilitating endocrine disorder caused by the excess production of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). In the majority of cases, the disease is caused by a non-cancerous tumor on the pituitary gland.

EMA: Novartis Flu Vaccine OK

December 3, 2014 1:30 pm | News | Comments

Europe's drug regulator says there is no proof that a flu vaccine for the elderly was linked to side effects, including deaths in Italy. Last week, Italy pulled two batches of Fluad, made by Switzerland's Novartis AG, after reports that people died after getting immunized.

Novartis Posts Strong Profit

October 28, 2014 7:35 am | by The Associated Press | News | Comments

Novartis AG has posted a 45 percent rise in net profit in the third quarter, boosted by strong sales of new products such as Gilenya for multiple sclerosis and the leukemia drug Tasigna. The Basel, Switzerland-based company's reported quarterly net profit was $3.24B

CSL to Acquire Novartis' Influenza Vaccine Business

October 27, 2014 8:43 am | News | Comments

CSL Limited today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.            

Advertisement

FDA Recommends Approval of Novartis’ AIN457 (secukinumab) for Moderate-to-Severe Plaque Psoriasis

October 20, 2014 3:28 pm | News | Comments

Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.

EU OKs Eli Lilly's $5.4B Bid for Novartis division

October 3, 2014 6:47 am | by The Associated Press | News | Comments

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors.

Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus

September 12, 2014 8:09 am | News | Comments

The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

Merus Labs Acquire Sintrom from Novartis

September 8, 2014 8:49 am | News | Comments

Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).          

Advertisement

Ophthotech Achieves $50M Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®

September 8, 2014 8:07 am | News | Comments

Ophthotech Corporation today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).

FDA Reviewing What Could Be First Biosimilar Drug

July 24, 2014 3:51 pm | News | Comments

Five years after Congress passed a law allowing biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.            

Novartis Cites Momentum in 3% Profit Rise

July 17, 2014 2:30 am | by The Associated Press | News | Comments

Novartis AG says its second-quarter profit rose 3 percent from a year earlier, reflecting solid growth and an increased focus on core products. The Basel-based company reports that profit during the April-June quarter rose to $3.28 billion, up from $3.18 billion in the same quarter of 2013.

Like Peanut Butter and Chocolate

July 16, 2014 3:02 pm | by Mike Auerbach, Editor In Chief | Blogs | Comments

Some things just seem to naturally go together – peanut butter and chocolate is one of those combinations – especially in the form of peanut butter cups. Bacon and eggs is another, as is peanut butter and jelly, pizza and beer and numerous other tasty combinations.

Novartis to Use Google Technology for Eye Care

July 15, 2014 8:51 am | by The Associated Press | News | Comments

The drugmaker said its Alcon eye care division will license Google technology and work with a team from Google to develop a lens that uses microchips and miniaturized electronics.            

Incyte Get $25M Milestone Payment from Novartis after Jakavi® Approval in Japan

July 8, 2014 9:01 am | News | Comments

Incyte Corporation announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis.      

Novartis Personalized Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation

July 7, 2014 3:18 pm | News | Comments

Novartis announced that the FDA has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

Ex-Novartis Pharma Employee Arrested Over Drug Data

June 11, 2014 8:19 am | News | Comments

Tokyo prosecutors arrested a former employee of Novartis Pharma K.K. on Wednesday on a charge of manipulating clinical study data leading to exaggerated claims in advertising for one of the firm's drugs.        

Italy Seeks $1.6B in Damages from Novartis and Roche

May 29, 2014 1:45 pm | News | Comments

Italy's health ministry is seeking 1.2 billion euros ($1.63 billion) in damages from Swiss pharmaceutical giants Novartis and Roche after an anti-trust court ruled the two companies colluded to prevent the distribution of an eye medication.  

Meningococcal Vaccine Market Expected To Hit $3.76B By 2019

May 9, 2014 9:34 am | News | Comments

According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.

FDA Approves Zykadia for Late-Stage Lung Cancer

April 29, 2014 4:16 pm | News | Comments

The FDA has granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells.

Deal Flurry Shows Drug Makers’ Move to Specialization

April 24, 2014 8:58 am | Videos | Comments

The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.            

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading